Jump to content
  • googleworkspace.png


    Formerly googleapps.png


    Volunteer Members of the RRDi who spend time actually volunteering may receive a Google Workspace account (formerly G Suite or Google Apps for Non Profits) which includes a free Gmail account with 30 GB of email and Google Drive storage. Your email could be YOUR_NAME@irosacea.org (if available).  Google Workspace uses our domain as the email address. 

    To request your Google Workspace account (includes the RRDi domain Gmail account) fill out the Join the RRDi. In the comment box mention the Google Workspace Gmail account email address you want. 

    Learn more by visiting this page, The RRDi and the Medical Digital Revolution, and scroll down the page to the subheading, G SUITE FOR NON PROFITS.

    To understand the Google for NON PROFITS click here

    For more info on G Suite click here.


  • Recently Browsing   0 members

    • No registered users viewing this page.

  • Forum Statistics

    • Total Topics
    • Total Posts
  • Posts

    • Cornea. 2024 Jul 5. doi: 10.1097/ICO.0000000000003627. Online ahead of print. ABSTRACT PURPOSE: The purpose of this study was to report the outcomes of quantum molecular resonance (QMR) electrotherapy in the management of refractory pediatric ocular rosacea. METHODS: This is a retrospective case series on 3 female pediatric patients (ages 12, 15, 14 years) with ocular rosacea. Two patients presented with corneal stromal neovascularization and punctate epithelial erosions while 1 patient presented with corneal scarring and paracentral stromal thinning. After failing conservative management, the patients were treated with 4 consecutive QMR electrotherapy sessions with the intensity set at 5 corresponding on average to a power of 12 W, with 60 V voltage and 200 mA current. Informed consent was obtained for off-label use. Patients were assessed for changes in vision, foreign body sensation, tearing, photophobia, and redness at each visit to determine symptomatic improvement. Outcome measures include best-corrected visual acuity, use of supplemental therapies (eg topical steroids) for symptom relief, extent of corneal neovascularization via serial slitlamp photography, and corneal scar remodeling via high resolution anterior segment optical coherence tomography (OCT). RESULTS: Two of the 3 patients experienced improvement in visual acuity after QMR electrotherapy. Corneal neovascularization and scarring regressed significantly in all 3 patients. Two months post-QMR electrotherapy, corneal remodeling was evident on optical coherence tomography in 2 patients. All 3 patients were able to discontinue topical immunosuppressants and remain symptom-free at 1.5 years of follow-up. CONCLUSIONS: QMR electrotherapy is a promising alternative in the treatment of refractory ocular rosacea in childhood and puberty, and it may potentiate corneal remodeling. PMID:38967538 | DOI:10.1097/ICO.0000000000003627 {url} = URL to article
    • J Alzheimers Dis. 2024 Jun 28. doi: 10.3233/JAD-240198. Online ahead of print. ABSTRACT This manuscript reviews the significant skin manifestations of Lewy body disease, including Parkinson's disease and dementia with Lewy bodies, and the diagnostic utility of skin biopsy. Besides classic motor and cognitive symptoms, non-motor manifestations, particularly dermatologic disorders, can play a crucial role in disease presentation and diagnosis. This review explores the intricate relationship between the skin and Lewy body disease. Seborrheic dermatitis, autoimmune blistering diseases (bullous pemphigoid and pemphigus), rosacea, and melanoma are scrutinized for their unique associations with Parkinson's disease, revealing potential links through shared pathophysiological mechanisms. Advances in diagnostic techniques allow the identification of promising biomarkers such as α-synuclein in samples obtained by skin punch biopsy. Understanding the dermatologic aspects of Lewy body disease not only contributes to its holistic characterization but also holds implications for innovative diagnostic approaches. PMID:38968048 | DOI:10.3233/JAD-240198 {url} = URL to article
    • JAAD Int. 2024 May 6;16:112-118. doi: 10.1016/j.jdin.2024.04.009. eCollection 2024 Sep. ABSTRACT PMID:38957837 | PMC:PMC11217679 | DOI:10.1016/j.jdin.2024.04.009 {url} = URL to article
    • Clin Cosmet Investig Dermatol. 2024 Jun 26;17:1551-1552. doi: 10.2147/CCID.S484236. eCollection 2024. ABSTRACT [This corrects the article DOI: 10.2147/CCID.S473598.]. PMID:38952412 | PMC:PMC11215658 | DOI:10.2147/CCID.S484236 {url} = URL to article
    • Heliyon. 2024 Jun 1;10(11):e32275. doi: 10.1016/j.heliyon.2024.e32275. eCollection 2024 Jun 15. ABSTRACT A combination of benzoyl peroxide (BPO) and tretinoin is recommended for treating acne; however, concurrent administration can be irritating, and coformulation is prevented by BPO-mediated oxidation of tretinoin. In rosacea, benzoyl peroxide has been shown to be efficacious; however, its use has been limited by poor tolerability. To overcome these limitations, the active ingredients can be encapsulated within silica microcapsules. The US Food and Drug Administration has approved 2 products using this technology, a combination of encapsulated benzoyl peroxide and encapsulated tretinoin product for acne vulgaris and encapsulated benzoyl peroxide to treat inflammatory lesions in rosacea. The active ingredients are released through small channels in the silica shell, gradually releasing the active ingredients to the skin. This study describes the stability and release profiles of encapsulated tretinoin and encapsulated benzoyl peroxide from the silica shell in physiologically relevant conditions and provides differentiation from traditional formulations. PMID:38947450 | PMC:PMC11214359 | DOI:10.1016/j.heliyon.2024.e32275 {url} = URL to article
  • Create New...

Important Information

Terms of Use